-
How Moderna's Patent Challenge Loss Could Impact Coronavirus Vaccine Program
Friday, July 24, 2020 - 11:25am | 564Read More...Moderna Inc (NASDAQ: MRNA) shares came under significant selling pressure Thursday afternoon following an adverse patent ruling, and the stock is adding to the losses in Friday's session. Moderna Loses Patent Challenge: In an ongoing legal dispute, the Patent Trial and Appeal Board...
-
Chardan: After Dicerna Pharma's 370% Run, Wait For Better Entry Point
Friday, March 9, 2018 - 10:50am | 433Read More...Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) could become a player in the emerging field of small RNA interference, or RNAi, according to Chardan Capital Markets. The Analyst Chardan analyst Keay Nakae started coverage of Dicerna with a Neutral rating and no price target...
-
Novavax Shares Rise 30% On Positive Data, But Risks Remain
Thursday, March 1, 2018 - 9:47am | 441Read More...Novavax, Inc. (NASDAQ: NVAX) popped 31 percent Wednesday evening after management announced the NanoFlu Vaccine demonstrated improved immune responses over alternative flu vaccines. Biotech experts disputed the data’s significance, with STAT News' Adam Feuerstein confessing skepticism. I...
-
Novavax Update Fails To Impress; This Is Now A 'Show Me Story'
Tuesday, July 25, 2017 - 12:02pm | 301Read More...Two analysts reiterated their Neutral ratings on Novavax, Inc. (NASDAQ: NVAX) after the company announced what it said was positive data for its phase 2 safety and immunogenicity trial of its RSV F vaccine. Novavax was down 24.5 percent and trading at $1.14 at the time of writing, one day after...
-
The Next Steps For OncoCyte After Better-Than-Expected Data
Tuesday, May 23, 2017 - 1:55pm | 487Read More...Shares of OncoCyte Corp (NYSE: OCX) were highly volatile Monday and Tuesday in reaction to the company presenting positive lung cancer blood test data to the American Thoracic Society. Keay Nakae of Chardan maintains a Buy rating on OncoCyte's stock with a price target raised from $5.50 to $7.50,...
-
4 Possible Catalysts On Eyegate's Horizon
Tuesday, December 6, 2016 - 12:17pm | 366Read More...Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) reported additional encouraging results from the Phase 1b/2a clinical study of its lead product, EGP-437, in patients who have undergone cataract surgery. Terming the lead compound as “promising,” Chardan Capital Markets' Keay Nakae...
-
Chardan Initiates Asterias Biotherapeutics At Buy On Potential Cell Therapy Competitiveness
Monday, May 23, 2016 - 11:46am | 478Read More...Chardan Capital Markets has started coverage of Asterias Biotherapeutics Inc (NYSE: AST) with a Buy rating and $5.50 price target, saying the company "has the potential to become a significant competitor in the emerging fields of cell therapy and regenerative medicine." "Asterias is developing...
-
Chardan Starts Coverage Of Mesoblast, Sees 'Large Market Opportunities'
Friday, February 19, 2016 - 10:21am | 257Read More...Chardan Capital’s Keay Nakae has initiated coverage of Mesoblast limited (ADR) (NASDAQ: MESO) with a Neutral rating and price target of $5.50. Nakae believes that there are several positives for the company, such as its proprietary mesenchymal lineage adult stem cells (MLCs), which can be...
-
StemCells Is Restructuring To Save Cash, But What's That Mean For Investors?
Thursday, December 24, 2015 - 10:34am | 305Read More...StemCells Inc (NASDAQ: STEM) shares are down 55 percent year-to-date. Chardan Capital Markets’ Keay Nakae maintained a Buy rating for the company, while reducing the price target to $1. The announced restructuring appears pragmatic, but there is concern around the potential future...
-
Chardan Initiates Eyegate Pharma At Buy, Sets $6 Target
Wednesday, December 23, 2015 - 8:54am | 331Read More...Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) shares are down 30 percent in the last three months, and have traded below $3 for most of December. Chardan Capital’s Keay Nakae initiated coverage of the company with a Buy rating and a price target of $6. Eyegate Pharma’s lead...
-
Chardan Starts Opexa Therapeutics With Buy Rating, $6 Price Target
Wednesday, November 4, 2015 - 9:41am | 326Read More...The share price of Opexa Therapeutics Inc (NASDAQ: OPXA) have declined 47.4 percent year-to-date, touching a low of $2.534 on August 24. Chardan Capital’s Keay Nakae has initiated coverage of the company with a Buy rating and price target of $6. Nakae views Tcelna as a “...
-
Time To Buy Signal Genetics? Chardan Thinks So
Tuesday, June 23, 2015 - 8:06am | 299Read More...In a report published Tuesday, Chardan Capital analyst Keay Nakae initiated coverage of Signal Genetics Inc. (NASDAQ: SGNL) with a Buy rating and $2.50 price target. The company has a "multi pronged" strategy to boost sales growth. The first strategy was to hire more sales people, along with plans...
-
Chardan Capital Markets Reiterates On Medical Transcription Billing
Monday, February 23, 2015 - 12:43pm | 266Read More...Chardan Capital Markets reiterated a Buy rating on Medical Transcription Billing Corp (NASDAQ: MTBC) Monday with a $6.25 price target. Analayst Keay Nakae noted that the company’s proprietary SaaS platform “provides fully-integrated services including mobile health (mHealth),...
-
UPDATE: Ascendiant Capital Markets Initiates Coverage On Aldeyra Therapeutics On Intriguing Investment Story
Wednesday, December 3, 2014 - 8:44am | 131Read More...In a report published Wednesday, Ascendiant Capital Markets analyst Keay Nakae initiated coverage on Aldeyra Therapeutics (NASDAQ: ALDX) with a Buy rating and $16.00 price target. In the report, Ascendiant Capital Markets noted, “We believe that Aldeyra Therapeutics is an intriguing speculative...
-
UPDATE: Ascendiant Capital Markets Reiterates On Repros Therapeutics Following Positive Topline Results
Friday, August 29, 2014 - 7:53am | 120Read More...In a report published Friday, Ascendiant Capital Markets analyst Keay Nakae reiterated a Buy rating on Repros Therapeutics (NASDAQ: RPRX), and raised the price target from $23.00 to $25.00. In the report, Ascendiant Capital Markets noted, “We believe that the positive result from the ZA-305 study...
